Dose Escalation Study of the NMDA Glycine-Site Antagonist Licostinel in Acute Ischemic Stroke

199989 citationsJournal Article

Authors

Gregory W. Albers · Marshfield Clinic

Wayne M. Clark · Mercy General Hospital

Richard P. Atkinson · INC Research (United States)

Kenneth P. Madden · Mercy General Hospital

Joann L. Data · INC Research (United States)

M.J. Whitehouse · Mercy General Hospital

Abstract

A short infusion of licostinel in doses up to 3.0 mg/kg is safe and tolerable in acute stroke patients. Licostinel may be a safer and better tolerated neuroprotective agent than many of the previously evaluated NMDA antagonists.

Topics & Keywords

Neuroscience and Neuropharmacology Research Neurological Disorders and Treatments Biochemical effects in animals

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Stroke

Volume 30, Issue 3, pp. 508-513

DOI: 10.1161/01.str.30.3.508

Field-Weighted Citation Impact: 1.94